Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The firm engages in the development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Collegium Pharmaceutical reports record 2022 performance and outlines growth strategies

Collegium Pharmaceutical's strong 2022 performance and strategic acquisitions position it for continued success in 2023 with a focus on growth.
The company's commercial strengths in key products like BELBUCA and Xtampza ER drive revenue and showcase growth potential.
Challenges in managing leverage, accelerating franchise growth, and navigating market dynamics are balanced by opportunities for expansion and innovation.
Analysts' inquiries reflect interest in Collegium Pharmaceutical's strategies, market positioning, and response to regulatory changes for future growth.

Collegium Pharmaceutical reports record Q1 revenue amidst patent challenges

Collegium Pharmaceutical's Q1 2023 performance showcased record revenue and strong financial management strategies.
The company faces challenges from patent infringement risks and generic competition, requiring a focus on defending IP and market positioning.
Opportunities in volume growth, business development, and strategic investments in key products position Collegium for long-term success.
Maintaining a balance between defending IP, managing expenses, and driving growth will be crucial for Collegium's future performance.

Collegium Pharmaceutical posts record revenue and growth, eyes strategic acquisitions

Collegium Pharmaceutical reported strong financial performance in Q2 2023, with a focus on achieving a banner year. Despite challenges with Xtampza ER and growth expectations, the company remains committed to improving access, reducing debt, and returning capital to shareholders.

Collegium Pharmaceutical excels in Q3, eyes growth opportunities ahead

Collegium Pharmaceutical reports strong Q3 2023 performance with record revenue and EBITDA growth, driven by successful contract renegotiations and operational efficiency.
Challenges include mitigating declining scripts, navigating patient profiles, and sustaining growth amidst market uncertainties, requiring strategic adjustments and foresight.
Opportunities lie in Medicare Part D market expansion, differentiated asset focus, and strategic valuations, positioning Collegium for future growth and market leadership.

Collegium Pharmaceutical reports record revenue and strategic wins in pain management market

Collegium Pharmaceutical's Q4 2023 earnings call highlighted exceptional financial achievements, robust product performance, and strategic wins in the pain management market. While facing challenges in maintaining guidance and addressing analyst queries, the company remains optimistic about its future outlook and growth potential.

Collegium Pharmaceutical reports strong Q1 earnings amidst leadership transition

Collegium Pharmaceutical's Q1 2024 earnings call highlighted strong financial performance, leadership transition, and growth strategies.
Despite challenges such as CEO resignation and competitive landscape dynamics, the company remains focused on its market position and growth potential.
Opportunities for business development priorities and strategic partnerships offer avenues for future growth and expansion.

Collegium Pharmaceutical reports record Q3 performance and navigates market challenges

Collegium Pharmaceutical's Q3 performance showcased robust financial results and strategic moves to strengthen their market position. While facing challenges in formulary changes and market competition, the company is well-positioned to leverage opportunities in the ADHD market and drive continued growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Collegium Pharmaceutical Is A Relatively Safe Opioid Pick For 2020

This biotech stock is promising strong revenue figures and a net profit for 2020.

Collegium Pharmaceutical Just Updated Its 2020 Guidance. Is It a Buy?

– Xtampza® ER Revenues Expected in the Range of $150.0 Million to $160.0 Million for 2020 –

Collegium Provides 2020 Financial Guidance

Market Is Turning A Blind Eye To Collegium's Lack Of Debt And Opioid Lawsuits

Bloom Energy

Sportsman's Warehouse Hlds

Buying proven businesses is better than scouring the pink sheets looking for a viable investment.

About to Buy Penny Stock ? Look at These 3 Companies First: BE, COLL & SPWH

Market Diagnoses Collegium's Opportunity

Investors are excited about the drugmaker's big formulary wins for its abuse-deterrent opioid drug.

Why Collegium Pharmaceutical Stock Is Crushing It Today

Collegium Pharmaceutical, Inc. (COLL) CEO Joseph Ciaffoni on Q3 2019 Results - Earnings Call Transcript

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -12.50% and -1.76%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Reports Q3 Loss, Misses Revenue Estimates

Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?

As most of the opioid manufacturers are under siege in court battles, Collegium is claiming their market share and recording impressive revenue growth.

Collegium: As Longstanding Opioid Companies Go Belly-Up, Collegium Looks To Stand Out

STOUGHTON, Mass., Aug.  29, 2019  (GLOBE NEWSWIRE) --  Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that four poster presentations relating to rates of abuse and diversion of Xtampza® ER (oxycodone), Nucynta® ER (tapentadol) and Nucynta® (tapentadol) relative to other opioids will be presented at the 13th annual PAINWeek National Conference taking place Sept. 3-7, 2019 in Las Vegas, NV. The posters will be presented on Thursday, Sept. 5th from 6:30 p.m. to 8:30 p.m. PT.

Collegium Announces Scientific Presentations at PAINWeek 2019 National Conference

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q2 2019 Results - Earnings Call Transcript

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 152.63% and -1.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Q2 Earnings Surpass Estimates

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Collegium Pharmaceutical (COLL) Q2 Earnings Expected to Decline

Collegium's recent selloff has provided me an opportunity to finally initiate a position in a long-time watch list stock.

Collegium Pharmaceutical, Inc.: Getting A Second Chance To Buy

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2019 Results - Earnings Call Transcript

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 83.33% and 6.29%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Reports Q1 Loss, Tops Revenue Estimates

Allogene Therapeutics Inc

Investment-bank analysts think these drugmakers are worth a lot more than the stock market does at the moment.

2 Big Biotech Stock Upgrades: Can They Reach These Targets?

Collegium Pharmaceutical (COLL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

News for Collegium Pharmaceutical Stock (COLL)